

Express Mail No.: EV335856352US

LIST OF REFERENCES CITED BY APPLICANT					ATTY DOCKET NO.		APPLICATION NO	
(Use several sheets if necessary)					10177-180-999		10177-180-999	
					APPLICANT			
					Tom			
					FILING DATE		GROUP	
					01/17/03 12/30/03		3752	
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
SBB	AA	3,773,034	11/20/73	Burns <i>et al.</i>				
	AB	3,952,742	04/27/76	Taylor				
	AC	4,296,100	10/20/81	Franco				
	AD	4,531,936	07/30/85	Gordon				
	AE	4,657,536	04/14/87	Dorman				
	AF	4,770,653	09/13/88	Shurman				
	AG	4,911,148	03/27/90	Sosnowski <i>et al.</i>				
	AH	4,946,442	08/07/90	Sanagi				
	AI	4,994,033	02/19/91	Shockey <i>et al.</i>				
	AJ	5,061,273	10/29/91	Yock				
	AK	5,185,004	02/09/93	Lashinski				
	AL	5,203,772	04/20/93	Hammerslag <i>et al.</i>				
	AM	5,244,460	09/14/93	Unger <i>et al.</i>				
	AN	5,385,148	01/31/95	Lesh <i>et al.</i>				
	AO	5,419,777	05/30/95	Holling				
	AP	5,489,575	02/06/96	Lee <i>et al.</i>				
	AQ	5,499,971	03/19/96	Stapland <i>et al.</i>				
	AR	5,507,724	04/16/96	Hofmann <i>et al.</i>				
	AS	5,569,160	10/29/96	Sauer <i>et al.</i>				
	AT	5,569,217	10/29/96	Luther				
	AU	5,571,215	11/05/96	Sternun <i>et al.</i>				
	AV	5,591,195	01/07/97	Taheri <i>et al.</i>				
	AW	5,653,684	08/05/97	Laplewicz <i>et al.</i>				
	AX	5,661,133 B1	08/26/97	Leiden <i>et al.</i>				
	AY	5,662,124	09/02/97	Wilk				
	AZ	5,693,029	12/02/97	Leonhardt				
	BA	5,698,531	12/16/97	Nabel <i>et al.</i>				
	BB	5,733,250		Withdrawn				
	BC	5,733,280	03/31/98	Avnall				
	BD	5,797,870	08/25/98	March <i>et al.</i>				
BE	5,797,960	08/25/98	Stevens <i>et al.</i>					
BF	5,820,592	10/13/98	Hammerslag					
BG	5,827,216	10/27/98	Igo <i>et al.</i>					
BH	5,830,593	11/03/98	Blecha <i>et al.</i>					
BI	5,833,658	11/10/98	Levy <i>et al.</i>					


Express Mail No.: EV335856352US

✓	BJ	5,840,031	11/24/98	Crowley				
	BK	5,840,059	11/24/98	March <i>et al.</i>				
	BL	5,840,062	11/24/98	Gumaste <i>et al.</i>				
	BM	5,843,050	12/01/98	Jones <i>et al.</i>				
	BN	5,846,221	12/08/98	Snoke <i>et al.</i>				
	BO	5,857,464	01/12/99	Desai				
	BP	5,860,953	01/19/99	Snoke <i>et al.</i>				
	BQ	5,871,495	02/16/99	Mueller				
	BR	5,876,373	03/02/99	Giba <i>et al.</i>				
	BS	5,882,332	03/16/99	Wijay				
	BT	5,885,272	03/23/99	Aita <i>et al.</i>				
	BU	5,891,133	04/06/99	Murphy-Chutorian				
	BV	5,931,831	08/03/99	Linder				
	BW	5,935,063	08/10/99	Nguyen				
	BX	5,941,845	08/24/99	Tu <i>et al.</i>				
	BY	5,941,868	08/24/99	Kaplan <i>et al.</i>				
	BZ	5,964,754	10/12/99	Osypka				
	CA	5,971,983	10/26/99	Lesh				
	CB	5,993,443	11/30/99	Murphy-Chutorian <i>et al.</i>				
	CC	5,997,525	12/07/99	March <i>et al.</i>				
	CD	6,004,269	12/21/99	Crowley <i>et al.</i>				
	CE	6,012,457	01/11/00	Lesh				
	CF	6,024,703	02/15/00	Zanelli <i>et al.</i>				
	CG	6,063,022	05/16/00	Ben-Haim				
	CH	6,133,233	10/17/00	Ross <i>et al.</i>				
	CI	6,183,444	02/06/01	Glines <i>et al.</i>				
	CJ	6,161,543	12/19/00	Cox <i>et al.</i>				
	CK	6,171,303	01/09/01	Ben-Haim <i>et al.</i>				
	CL	6,179,809	01/30/01	Khairkhahan <i>et al.</i>				
	CM	6,224,584 B1	05/01/01	March <i>et al.</i>				
	CN	6,237,605 B1	05/29/01	Vaska <i>et al.</i>				
	CO	6,309,375	10/30/01	Glines <i>et al.</i>				
✓	CP	6,314,962 B1	11/13/01	Vaska <i>et al.</i>				
✓	CQ	6,314,963 B1	11/13/01	Vaska <i>et al.</i>				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
✓	CR	WO 96/32129	10/17/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CS	WO 97/25101	07/17/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CT	WO 97/47253	12/18/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CU	WO 99/39624	08/12/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
✓	CV	WO 00/57895	10/05/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>

Express Mail No.: EV335856352US

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
506	CW	Padua <i>et al.</i> , "Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury" <i>Molecular and Cellular Biochemistry</i> 143 : 129-135 (1995)
	CX	Shi <i>et al.</i> , "PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47phox" <i>Proc. Natl. Acad. Sci.</i> 93 :6014-6018 (1996)
	CY	Uchida <i>et al.</i> , "Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: An experimental study" <i>Am. Heart J.</i> , 130 :1182-1188 (1995)
	CZ	Unger <i>et al.</i> , "Basic fibroblast growth factor enhances myocardial collateral flow in a canine model" <i>Am J. Physiol.</i> , 266 :H1577-H1595 (1994)
	DA	Walterberger <i>et al.</i> , "Ischemia-Induced Transplant Arteriosclerosis in the Rat" <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> 16 (12):1516-1523 (1996)
9	DB	Xiaobing, <i>et al.</i> , "Ischemia and Reperfusion reduce the Endogenous Basic Fibroblast Growth Factor (bFGF) in Rat Skeletal Muscles" <i>Chinese Medical Journal</i> 108 (9): 699-703, (1995)
EXAMINER 		DATE CONSIDERED 12/20/06
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Express Mail No.: EV335856352US


LIST OF REFERENCES CITED BY APPLICANT				ATTY DCKET NO. 243-999 10177-180-999		APPLICATION NO. 10/347,567,749,327	
(Use several sheets if necessary)				APPLICANT Tom		FILING DATE 01/17/03 12/30/03	
				GROUP 3752			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EJO	DC	4,163,204	07/31/79	Sudo et al.			
	DD	4,320,392	03/16/82	Giovinazzo et al.			
	DE	4,469,091	09/04/84	Slaneitz, Jr			
	DF	4,736,640	04/12/88	Hooks			
	DG	4,763,534	08/16/88	Hager			
	DH	4,847,586	07/11/89	Tanaga et al.			
	DI	4,904,184	02/27/90	Murphy et al.			
	DJ	5,339,799	08/23/94	Kami et al.			
	DK	5,341,687	08/30/94	Stan			
	DL	5,396,887	03/14/95	Imran			
	DM	5,414,940	05/16/95	Sturdevant			
	DN	5,429,006	07/04/95	Tamori			
	DO	5,520,188	05/28/96	Hennige et al.			
	DP	5,526,703	06/18/96	Aslam et al.			
	DQ	5,553,500	09/10/96	Grahn et al.			
	DR	5,578,766	11/26/96	Kondo			
	DS	5,583,303	12/10/96	Franz			
	DT	5,604,314	02/18/97	Grahn			
	DU	5,645,531	7/97	Thompson et al.			
	DV	5,725,523	03/10/98	Mueller			
	DW	5,755,714	05/26/98	Murphy-Chutorian			
	DX	5,855,577	01/05/99	Murphy-Chutorian et al.			
	DY	5,886,615	03/23/99	Burgess			
	DZ	5,891,133	04/06/99	Murphy-Chutorian			
	EA	5,925,012	07/20/99	Murphy-Chutorian			
	EB	5,989,700	11/23/99	Krivopal			
EC	6,024,703	02/15/00	Zanelli et al.				
ED	6,171,276	01/01	Lippe et al.				
EE	6,309,370	10/01	Haim et al.				
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
EJO	EP	WO A 9939624	8/12/99	PCT			<input type="checkbox"/> <input type="checkbox"/>

Express Mail No.: EV335856352US

506	EG	EP 0 442 015	2/16/96	EPO			<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER



DATE CONSIDERED

12/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.